Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05455918 | Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor | recruiting | Phase 2 | 42 | Yonsei UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05392413 |
| Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody |
| recruiting |
| — |
| 200 |
| Nanfang Hospital, Southern Medical UniversityOTHER |
| 1 |
| Jul 6, 2022 |
| clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05352321 | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | recruiting | N/A | 264 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05431257 | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling(LD-VenEx) | recruiting | Phase 2 | 117 | Rigshospitalet, DenmarkOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer(AMENDER) | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02354274 | Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine® | recruiting | N/A | 330 | Olfred HansenOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04666961 | Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ(HORNEO01) | recruiting | Phase 2 | 262 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05323929 | The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma | recruiting | N/A | 200 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05323201 | Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | recruiting | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04946773 | Deep Liver Phenotyping and Immunology Study(DELPHI) | recruiting | — | 100 | University of OxfordOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05291728 | Screening for Early Gastric Cancer in Shaanxi Province | recruiting | — | 12,500,000 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03983226 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | recruiting | Phase 2 | 167 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04475705 | Propofol vs Sevo for Paediatric Tumor Surgery | recruiting | Phase 4 | 100 | Hong Kong Children's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05214885 | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma | recruiting | — | 300 | Qianfoshan HospitalOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05266534 | The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets(myomectomy) | recruiting | N/A | 162 | Wael Elbanna ClinicOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03785743 | Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma | recruiting | N/A | 200 | Tongji HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05260619 | Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma(PCNSL-LEM) | recruiting | Phase 2 | 28 | Seoul National University Bundang HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04179929 | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | recruiting | N/A | 300 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05221372 | ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)(START-TKI) | recruiting | — | 1,300 | Erasmus Medical CenterOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04712305 | Urine Omics Predicting IO Therapy Responses in mRCC Patients | recruiting | — | 400 | National Taiwan University HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05184400 | Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer(CHOCA) | recruiting | — | 500 | Herlev and Gentofte HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05155878 | Prognostic Factors in Periampullary Tumors and Cysts | recruiting | — | 500 | Umeå UniversityOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC | recruiting | Phase 4 | 70 | University of CreteOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04769947 | Italian Treatment Free Remission Registry | recruiting | — | 800 | University of Turin, ItalyOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT05126160 | Immune Score Based Radiomics in Nasopharyngeal Carcinoma | recruiting | — | 494 | Zhejiang Cancer HospitalOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04018872 | Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer | recruiting | Phase 2 | 78 | Dallas VA Medical CenterFED | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | recruiting | Phase 3 | 537 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2022source: clinicaltrials